Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Intensity Chemotherapy with Short-Course Blinatumomab for Ph- B-ALL
NCT06930105Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Nov 2027
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
A Phase 2 trial of blinatumomab in Acute B-cell lymphoblastic leukemia (B-ALL). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
Acute B-cell lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06930105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930105.